Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas
E. N. Bonglack, J. E. Messinger, J. M. Cable, M. Parnell, J. Ch'ng, H. R. Christofk, M. A. Luftig
This study shows that inhibiting MCT1 and MCT4 in EBV-driven lymphomas disrupts metabolism, leading to growth arrest and sensitization to metformin, revealing a potential therapeutic strategy.
bioRxiv · Dec 4, 2020Cancer Biology